Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, and dyslipidemia. MASLD often leads to fibrosis, cirrhosis, and hepatoc...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Elizabeta Knezović, Marija Hefer, Suzana Blažanović, Ana Petrović, Vice Tomičić, Nika Srb, Damir Kirner, Robert Smolić, Martina Smolić
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2025-02-01
סדרה:	Current Issues in Molecular Biology
נושאים:	MASLD MASH resmetirom THR-β agonists
גישה מקוונת:	https://www.mdpi.com/1467-3045/47/3/154
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!